OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Iyer on Unmet Needs for Patients With TSC1/2-mutated Solid Tumors

December 23rd 2022

Gopa Iyer, MD, discusses the unmet needs for patients with solid tumors harboring TSC1/2 mutations.

Dr. Shaughnessy on the Potential of the FELIX Trial to Address Unmet Needs in B-ALL

December 23rd 2022

Paul J. Shaughnessy, MD, discusses the potential of the phase 1/2 FELIX trial to address unmet needs in relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr. Chaudhary on the Correlation of PD-L2 Status and PFS Rates in ER+ Breast Cancer

December 21st 2022

Lubna N. Chaudhary, MD, discusses the correlation between PD-L2 status and progression-free survival rates in treatment-naïve estrogen receptor–positive breast cancer.

Dr. Gadi on the Investigation of AMUN-003 in TNBC

December 21st 2022

Vijayakrishna Gadi, MD, PhD, discusses the investigation of AMUN-003 in triple-negative breast cancer.

Dr. Bardia on the Ongoing Investigation of Oral SERDs in ER+/HER2- Breast Cancer

December 19th 2022

Aditya Bardia, MD, MPH, discusses the investigation of oral selective estrogen receptor degraders in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.

Dr. Kaklamani on the Evolution of Oral SERDs in ER+ Breast Cancer

December 19th 2022

Virginia G. Kaklamani, MD, discusses the evolution of oral selective estrogen receptor degraders in estrogen receptor-positive breast cancer.

Dr. Rampal on the Importance of Clinical Trial Enrollment in Myelofibrosis

December 19th 2022

Raajit K. Rampal, MD, PhD, discusses the importance of clinical trial enrollment in patients with myelofibrosis.

Dr. Oh on Pacritinib in Myelofibrosis

December 19th 2022

Stephen T. Oh, MD, PhD, discusses the benefits of pacritinib in patients with myelofibrosis.

Dr. Palmer on Symptom Burden in Myelofibrosis With Thrombocytopenia

December 19th 2022

Jeanne M. Palmer, MD, discusses total symptom scores in patients with myelofibrosis with thrombocytopenia.

Dr. Burke on the Underrepresentation of Elderly Patients in Clinical Trials for Lymphoma

December 19th 2022

John M. Burke, MD, discusses the underrepresentation of elderly patients in clinical trials for lymphoma.

Dr. Niemann on Ibrutinib Plus Venetoclax Vs Chlorambucil and Obinutuzumab in Mutated CLL

December 19th 2022

Carsten Niemann, MD, PhD, discusses ibrutinib plus venetoclax vs chlorambucil and obinutuzumab in mutated chronic lymphocytic leukemia.

Dr. Saltman on the Use of the DetermaIO Assay to Inform Immunotherapy Use in Advanced-Stage NSCLC

December 19th 2022

David L. Saltman, MD, PhD, discusses the use of the 27-gene Determa immuno-oncology assay to inform use of single-agent immunotherapy in patients with advanced-stage non–small cell lung cancer.

Dr. Sauter on Pembrolizumab After Stem Cell Transplant in T-Cell NHL

December 19th 2022

Craig Sauter, MD, discusses the investigation of pembrolizumab given after stem cell transplant in T-cell non-Hodgkin lymphoma.

Dr. Leslie on the 3-Year Follow-Up of the ZUMA-5 Trial in R/R iNHL

December 19th 2022

Lori A. Leslie, MD, discusses the 3-year follow-up data of the phase 2 ZUMA-5 trial in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Dr. Mian on the Investigation into the Synchronous Up-front Setting of Metastatic Prostate Cancer

December 19th 2022

Omar Mian, MD, PhD, discusses the ongoing investigation into the synchronous up-front setting of metastatic prostate cancer.

Dr. Contreras on Neoadjuvant Therapies in Basal Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

December 19th 2022

Carlo Contreras, MD, discusses areas of planned and ongoing research with neoadjuvant therapies in basal cell carcinoma and cutaneous squamous cell carcinoma.

Dr. Rimel on the Importance of BRCA and HRD Testing in Ovarian Cancer

December 19th 2022

Bobbie J. Rimel, MD, discusses the importance of testing patients with ovarian cancer for homologous recombination deficiency (HRD) or homologous recombination proficiency (HRP), and BRCA mutation status.

Dr. Cheah on the Investigation of BGB-11417 With or Without Zanubrutinib in CLL

December 16th 2022

Chan Cheah, MBBS, discusses the investigation of BGB-11417 with or without zanubrutinib in chronic lymphocytic leukemia.

Dr. Aggarwal on Treating Patients With EGFR Mutations in NSCLC

December 15th 2022

Charu Aggarwal, MD, MPH, discusses treating patients with EGFR-mutant non–small cell lung cancer.

Dr. George on the Clinical Benefit of Phenotypic Evaluation in Prostate Cancer

December 15th 2022

Daniel J. George, MD, discusses the clinical benefits of evaluating phenotype in metastatic castration-resistant prostate cancer.